At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
In Brief
A Phase 2 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy, Cognitive Assessment, and 3 other interventions for Adult Giant Cell Glioblastoma and 2 related conditions. Completed, enrolled 125 participants across 110 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of vorinostat when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed glioblastoma multiforme. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vorinostat together with temozolomide and radiation therapy may kill more tumor cells.
Study Details
Timeline
Interventions
Undergo radiotherapy
Ancillary studies
Correlative studies
Given PO
Given PO